Christopher C. Caillouet

Array ( [id] => 8670632 [patent_doc_number] => 20130045169 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-02-21 [patent_title] => 'COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY' [patent_app_type] => utility [patent_app_number] => 13/492458 [patent_app_country] => US [patent_app_date] => 2012-06-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 65563 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13492458 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9469260 [patent_doc_number] => 08722892 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-05-13 [patent_title] => 'Processes and intermediates for preparing a macrocyclic protease inhibitor of HCV' [patent_app_type] => utility [patent_app_number] => 13/484881 [patent_app_country] => US [patent_app_date] => 2012-05-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12321 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13484881 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10032556 [patent_doc_number] => 09073863 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-07-07 [patent_title] => 'Cyanoquinoline compounds having activity in correcting mutant-CFTR processing and increasing ion transport and uses thereof' [patent_app_type] => utility [patent_app_number] => 14/122193 [patent_app_country] => US [patent_app_date] => 2012-05-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 19 [patent_no_of_words] => 30348 [patent_no_of_claims] => 57 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 10 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14122193 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8586902 [patent_doc_number] => 20130005724 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-01-03 [patent_title] => 'PYRIDINO-PYRIDINONE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF' [patent_app_type] => utility [patent_app_number] => 13/477778 [patent_app_country] => US [patent_app_date] => 2012-05-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21018 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13477778 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8382246 [patent_doc_number] => 20120225874 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-09-06 [patent_title] => 'BICYCLIC DERIVATIVES AS CETP INHIBITORS' [patent_app_type] => utility [patent_app_number] => 13/473649 [patent_app_country] => US [patent_app_date] => 2012-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34169 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13473649 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9603539 [patent_doc_number] => 20140200222 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-07-17 [patent_title] => 'N-LINKED QUINOLINEAMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS' [patent_app_type] => utility [patent_app_number] => 14/117265 [patent_app_country] => US [patent_app_date] => 2012-05-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16536 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14117265 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10045996 [patent_doc_number] => 09086390 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-07-21 [patent_title] => 'Dabigatran etexilate and related substances, processes and compositions, and use of the substances as reference standards and markers' [patent_app_type] => utility [patent_app_number] => 14/076761 [patent_app_country] => US [patent_app_date] => 2012-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16837 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 6 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14076761 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9671685 [patent_doc_number] => 20140235548 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-08-21 [patent_title] => 'COMPOSITIONS AND METHODS FOR JAMM PROTEIN INHIBITION' [patent_app_type] => utility [patent_app_number] => 14/117816 [patent_app_country] => US [patent_app_date] => 2012-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 94 [patent_figures_cnt] => 94 [patent_no_of_words] => 41225 [patent_no_of_claims] => 44 [patent_no_of_ind_claims] => 13 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14117816 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8490103 [patent_doc_number] => 20120289510 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-11-15 [patent_title] => 'Benzyl Amines, A Process For Their Production And Their Use As Anti-Inflammtory Agents' [patent_app_type] => utility [patent_app_number] => 13/465746 [patent_app_country] => US [patent_app_date] => 2012-05-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31599 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13465746 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9626630 [patent_doc_number] => 08796310 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-08-05 [patent_title] => 'Amino-pyridine-containing spleen tyrosine kinase (SYK) inhibitors' [patent_app_type] => utility [patent_app_number] => 13/704484 [patent_app_country] => US [patent_app_date] => 2012-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 40323 [patent_no_of_claims] => 38 [patent_no_of_ind_claims] => 14 [patent_words_short_claim] => 7 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13704484 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9686766 [patent_doc_number] => 20140243532 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-08-28 [patent_title] => 'NOVEL PRECURSORS OF GLUTAMATE DERIVATIVES' [patent_app_type] => utility [patent_app_number] => 14/115127 [patent_app_country] => US [patent_app_date] => 2012-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14808 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14115127 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9355575 [patent_doc_number] => 08674108 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-03-18 [patent_title] => 'Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide' [patent_app_type] => utility [patent_app_number] => 13/452758 [patent_app_country] => US [patent_app_date] => 2012-04-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 39 [patent_figures_cnt] => 39 [patent_no_of_words] => 36390 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 97 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13452758 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9910278 [patent_doc_number] => 20150065480 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-03-05 [patent_title] => 'MIF INHIBITORS AND THEIR USES' [patent_app_type] => utility [patent_app_number] => 14/237136 [patent_app_country] => US [patent_app_date] => 2012-04-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 35333 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14237136 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8701737 [patent_doc_number] => 08394959 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-03-12 [patent_title] => 'Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-2-buteramide and crystalline forms thereof' [patent_app_type] => utility [patent_app_number] => 13/441168 [patent_app_country] => US [patent_app_date] => 2012-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 10017 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 169 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13441168 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9232901 [patent_doc_number] => 08598205 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-12-03 [patent_title] => 'Modulators of cystic fibrosis transmembrane conductance regulator' [patent_app_type] => utility [patent_app_number] => 13/439379 [patent_app_country] => US [patent_app_date] => 2012-04-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22271 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 5 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13439379 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8302021 [patent_doc_number] => 20120184579 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-07-19 [patent_title] => 'Quinolines and Their Therapeutic Use' [patent_app_type] => utility [patent_app_number] => 13/435242 [patent_app_country] => US [patent_app_date] => 2012-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27653 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13435242 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8909678 [patent_doc_number] => 08481742 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-07-09 [patent_title] => 'Fused aromatic PTP-1B inhibitors' [patent_app_type] => utility [patent_app_number] => 13/418956 [patent_app_country] => US [patent_app_date] => 2012-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13547 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13418956 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9643275 [patent_doc_number] => 20140221387 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-08-07 [patent_title] => 'COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES' [patent_app_type] => utility [patent_app_number] => 14/003733 [patent_app_country] => US [patent_app_date] => 2012-03-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 32089 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14003733 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8482816 [patent_doc_number] => 20120282223 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-11-08 [patent_title] => 'Amorphous (5-Fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-Acetic Acid' [patent_app_type] => utility [patent_app_number] => 13/414328 [patent_app_country] => US [patent_app_date] => 2012-03-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 19790 [patent_no_of_claims] => 34 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13414328 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8630180 [patent_doc_number] => 08362253 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-01-29 [patent_title] => 'Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide' [patent_app_type] => utility [patent_app_number] => 13/413327 [patent_app_country] => US [patent_app_date] => 2012-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 52 [patent_figures_cnt] => 52 [patent_no_of_words] => 19944 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13413327 [rel_patent_id] =>[rel_patent_doc_number] =>)